Market closed
Arcus Biosciences/RCUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcus Biosciences
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Ticker
RCUS
Sector
Trading on
NYSE
Industry
Biotechnology
Headquarters
Employees
577
Website
RCUS Metrics
BasicAdvanced
$1.6B
Market cap
-
P/E ratio
-$3.05
EPS
0.89
Beta
-
Dividend rate
Price and volume
Market cap
$1.6B
Beta
0.89
52-week high
$20.31
52-week low
$12.95
Average daily volume
686K
Financial strength
Current ratio
5.136
Quick ratio
5.035
Long term debt to equity
3.15
Total debt to equity
4.882
Interest coverage (TTM)
-136.50%
Management effectiveness
Return on assets (TTM)
-14.18%
Return on equity (TTM)
-41.47%
Valuation
Price to revenue (TTM)
5.736
Price to book
2.49
Price to tangible book (TTM)
2.49
Price to free cash flow (TTM)
-5.306
Growth
Revenue change (TTM)
104.13%
Earnings per share change (TTM)
-22.74%
3-year revenue growth (CAGR)
38.52%
3-year earnings per share growth (CAGR)
0.31%
What the Analysts think about RCUS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Arcus Biosciences stock.
RCUS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RCUS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RCUS News
AllArticlesVideos
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire·3 hours ago
First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
Business Wire·12 hours ago
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
Business Wire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Arcus Biosciences stock?
Arcus Biosciences (RCUS) has a market cap of $1.6B as of October 24, 2024.
What is the P/E ratio for Arcus Biosciences stock?
The price to earnings (P/E) ratio for Arcus Biosciences (RCUS) stock is 0 as of October 24, 2024.
Does Arcus Biosciences stock pay dividends?
No, Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders as of October 24, 2024.
When is the next Arcus Biosciences dividend payment date?
Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcus Biosciences?
Arcus Biosciences (RCUS) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.